AbbVie (ABBV) is up 3.3% today. Here is some analysis on what might have caused this price movement. ([investors.abbvie.com](https://investors.abbvie.com/news-releases/news-release-details/abbvie-host-second-quarter-2026-earnings-conference-call?utm_source=openai))
Analysis: The move appears tied to a mix of bullish Wall Street sentiment and continued pipeline momentum ahead of AbbVie’s second-quarter earnings report on July 31. Recent price-target increases highlighted strength in AbbVie’s immunology business, while fresh regulatory filings added to the view that newer growth drivers can keep offsetting Humira erosion. ([investing.com](https://www.investing.com/news/stock-market-news/why-is-abbvie-stock-climbing-today-93CH-4788764?utm_source=openai))
Details:
Sources:
AbbVie, Investing.com, Benzinga
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ABBV Insider Trading Activity
$ABBV insiders have traded $ABBV stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 3 sales selling 18,668 shares for an estimated $4,375,549.
- DAVID RYAN PURDUE (SVP, Controller) sold 5,230 shares for an estimated $1,221,518
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ABBV Hedge Fund Activity
We have seen 1,744 institutional investors add shares of $ABBV stock to their portfolio, and 1,711 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 12,202,446 shares (-48.5%) from their portfolio in Q1 2026, for an estimated $2,642,195,632
- FISHER ASSET MANAGEMENT, LLC added 8,463,716 shares (+1347.0%) to their portfolio in Q1 2026, for an estimated $1,832,648,425
- WELLINGTON MANAGEMENT GROUP LLP removed 8,028,867 shares (-53.8%) from their portfolio in Q1 2026, for an estimated $1,738,490,571
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 7,827,781 shares (-87.8%) from their portfolio in Q1 2026, for an estimated $1,694,949,419
- CAPITAL RESEARCH GLOBAL INVESTORS added 5,846,586 shares (+23.0%) to their portfolio in Q1 2026, for an estimated $1,265,961,266
- DIAMANT ASSET MANAGEMENT, INC. added 3,654,351 shares (+21649.0%) to their portfolio in Q1 2026, for an estimated $791,276,622
- UBS GROUP AG added 3,524,276 shares (+33.5%) to their portfolio in Q1 2026, for an estimated $763,111,482
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ABBV Government Contracts
We have seen $293,755 of award payments to $ABBV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROSTHETIC ORDER - IMPLANT ITEMS: $15,758
- 4569321051!NATRELLE INSPIRA SCF 605CC BREAST IMPLAN: $4,014
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
$ABBV Congressional Stock Trading
Members of Congress have traded $ABBV stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/05.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$ABBV Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 11 analysts offer price targets for $ABBV in the last 6 months, with a median target of $265.0.
Here are some recent targets:
- Vamil Divan from Guggenheim set a target price of $261.0 on 07/09/2026
- Chris Schott from JP Morgan set a target price of $280.0 on 07/09/2026
- Carter Gould from Cantor Fitzgerald set a target price of $265.0 on 07/06/2026
- Gary Nachman from Canaccord Genuity set a target price of $273.0 on 06/23/2026
- David Amsellem from Piper Sandler set a target price of $298.0 on 06/23/2026
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $235.0 on 05/15/2026
- Terence Flynn from Morgan Stanley set a target price of $278.0 on 04/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
